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Abstract The coding sequence for chloramphenicol acetyl
transferase (CAT) contains several rare codons; three of them
are ATA encoding isoleucine in positions 13, 84 and 119 of the
amino acid sequence. Expression of CAT on Escherichia coli
ribosomes in vitro results in mostly full-length product but also
distinct smaller polypeptides from less than 3 kDa to over 20
kDa. As reported earlier, the smaller polypeptides are the
predominant products, if translation is initiated with fluoro-
phore-Met-tRNAf. All this translational pausing is eliminated
when the first ATA codon is mutated to ATC, a frequently used
codon for isoleucine in E. coli. Addition of large amounts of
E. coli tRNA to the coupled transcription/translation reaction
does not reduce the number of pause-site peptides seen in the
expression of wild-type CAT. Thus we hypothesize that the
mRNA structure may be an important determinant for
translational pausing. ß 2002 Published by Elsevier Science
B.V. on behalf of the Federation of European Biochemical So-
cieties.
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1. Introduction
Non-random size distribution of nascent peptides generat-
ing a speci¢c pattern for a given coding sequence was ob-
served during coupled transcription/translation on Escherichia
coli ribosomes (exempli¢ed and reviewed in [1]). Possible rea-
sons for translational pausing as presented in the literature
were brie£y reviewed [2]. The main two aspects discussed in
this regard are either mRNA secondary structure or rare co-
dons and low abundance of the corresponding tRNA. It has
been well substantiated that a strong correlation exists be-
tween the frequency of codon usage and the level of its cog-
nate tRNA [3]. The di¡erential population of isoaccepting
tRNA molecules has been suggested to be the key factor in
regulating the relative translational rate of synonymous co-
dons [4^6]. It has been observed earlier that in the absence
of appropriate acylated rare tRNA species, ribosomes would
pause at a speci¢c site [7^11]. The e¡ect of the rare arginine
codons AGG and AGA [12,13] and the rare isoleucine codon
AUA [14] on protein translation has been characterized. It has
also been reported that rare codons located in the slow re-
gions of the mRNA tend to form higher order secondary
structures that might provide an additional time pause for
the ribosome to move through the critical region [15,16].
We noticed enhanced low mass nascent polypeptides when
chloramphenicol acetyl transferase (CAT) synthesis was initi-
ated with £uorophore-Met-tRNAf [2,17]. It was hypothesized
that a hydrophobic residue like coumarin at the N-terminus of
CAT may interfere with the passage of the nascent peptide
through the tunnel in the large ribosomal subunit [2]. Pyrene
covalently attached to the N-terminal methionine had even a
greater e¡ect on translational pausing when CAT was synthe-
sized than the other £uorophores tested [17]. Translational
pausing of CAT was also enhanced, when the amount of
cell extract used in the coupled transcription/translation assay
was reduced [2]. In a separate study, translational pausing as
observed on E. coli ribosomes was not seen, when the same
coding sequences were expressed either in the wheat germ or
rabbit reticulocyte lysate [18]. CAT was included in this study.
Here we demonstrate that translational pausing during
CAT synthesis in the cell-free E. coli system can be a¡ected
by replacing a rare codon for isoleucine at position 13 of the
amino acid sequence of the protein. The silent mutagenesis,
changing one nucleotide in this codon without changing the
amino acid sequence, eliminates all pause-site peptides ob-
served during synthesis of wild-type CAT when initiated
with pyrene-Met-tRNA.
2. Materials and methods
2.1. Materials
N-(1-Pyrene)-maleimide was from Molecular Probes, Inc. (Eugene,
OR, USA). tRNAMetf , rifampicin and all other biochemicals were
from Sigma (St. Louis, MO, USA). [35S]Methionine was purchased
from NEN Life Science Products (Boston, MA, USA). [14C]L-Amino
acids (52 mCi/mmol C atom) and [3H]acetyl-coenzyme A (4.9 Ci/
mmol) were bought from Amersham Pharmacia Biotech (Boston,
MA, USA). Low molecular weight protein standards for SDS^
PAGE were from Promega (Madison, WI, USA). E. coli tRNA
from MRE-600 was purchased from Boehringer Mannheim (Ger-
many).
2.2. Methods
2.2.1. Plasmid constructs. Using the wild-type CAT sequence
cloned into pGEM-3Z as template, silently mutated CAT was gener-
ated using the primers (5P to 3P) TCA GGA GCT CAA GGA AGC
TAA AAT GGA GAA AAA AAT CAC TGG ATA TAC CAC CGT
TGA TAT CTC CCA ATG GCA TC and M13 as a reverse primer.
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The PCR product was digested with SacI and HindIII, then ligated
into pGEM-3Z that had been cut with the same enzymes. The mu-
tated CAT sequence was con¢rmed by sequencing carried out at the
UT sequencing center, Institute for Cellular and Molecular Biology,
at Austin, TX, USA.
2.2.2. Synthesis of £uorophore-Met-tRNAf species. Pyrene-succin-
imido-thiopropionate-Met-tRNAf (designated as pyrene-Met-tRNA
in the text) was synthesized as described previously [17].
2.2.3. The cell-free system. The in vitro coupled transcription/
translation assays were performed as described in [17]. Pyrene-
[35S]Met-tRNA (2500 Ci/mol) or [14C]L-amino acids (52 mCi/mmol
C atom) were used to initiate or trace protein synthesis. In the latter
case, the missing ¢ve amino acids (not included in the mixture of
15 radioactive amino acids) were added in unlabeled form each at
0.3 mM ¢nal concentration. Reaction mixtures contained 5 Wl of
A19 S30 unless stated otherwise. Incubation was for the indicated
length of time. Then an aliquot was withdrawn to determine the
amount of polypeptides synthesized. In the absence of plasmid, tri-
chloroacetic acid-insoluble material was less than 5% of the polypep-
tides formed in the presence of plasmid and these blank values were
subtracted. Another aliquot was prepared for SDS^PAGE in Tricine
bu¡er according to Scha«gger and von Jagow [19]. When CAT activity
was determined, 1 Wl of the reaction mixture after coupled transcrip-
tion/translation was used.
2.2.4. CAT enzyme assay. CAT enzyme activity was assayed by
the method of Sleigh [20]. The assays were performed at 30‡C for
10 min. The speci¢c enzymatic activities were calculated from the
amount of protein synthesized, the percentage of full-length product
formed and the units of enzyme activity obtained.
3. Results
3.1. Silent mutation of the ¢rst rare isoleucine codon eliminates
translational pausing
When CAT was synthesized in the E. coli cell-free system, a
distinct ladder of pause-site peptides was observed in size
from less than 3.0 kDa migrating close to the front of the
gel to near full size of 25 kDa [1,2,17,18]. Accumulation of
the smallest nascent peptide was pronounced, when protein
synthesis was initiated with £uorophore-[35S]Met-tRNA
[2,17]. Attempts were made to isolate this smallest peptide.
By mass spectral analysis, its molecular mass was found to
correspond to the ¢rst 12 amino acids of the CAT sequence
(Ramachandiran and Linse, unpublished results, manuscript
in preparation). Isoleucine, located at position 13 of the se-
quence, is coded by a rare AUA codon which has been clas-
si¢ed as the ¢fth rarest codon in E. coli mRNA occurring at a
frequency of 0.4% [21]. There are a total of 14 rare codons in
CAT of which three are the rare isoleucine ATA codons. In
general, CAT translational pause sites could not be correlated
with the positions of rare codons (data not shown). But the
correlation between the ¢rst ATA codon and the smallest of
the nascent pause peptides is more intriguing in light of its
accumulation (60^70% of the total protein produced) when
synthesized with pyrene-[35S]Met-tRNA.
To investigate whether this rare ATA codon at position 13
has an e¡ect on translational pausing, site-directed mutagen-
esis was carried out to silently mutate this codon to ATC. The
procedure is described in Section 2.2. The PCR product was
ligated into the same plasmid in the same position as the wild-
type CAT coding sequence. Mutant and wild-type coding se-
quences were expressed by coupled transcription/translation
with pyrene-[35S]Met-tRNA to initiate protein synthesis. The
translation products were analyzed by SDS^PAGE followed
by phosphorimaging. The results are presented in Fig. 1A.
They indicate that with the mutant CAT coding sequence,
over 90% of the synthesized polypeptides represent the full-
length protein (lane 3), whereas in the case of wild-type CAT,
the usual pattern of pause-site peptides is observed with less
than 10% full-length product (lane 1). When protein synthesis
was initiated with pyrene-Met-tRNA, reduction of the
amount of S30 in the assay had a strong e¡ect on the syn-
thesis of wild-type CAT polypeptides (lane 2); however, the
pattern seen with the mutated CAT coding sequence did not
change (lane 4). It should be pointed out that the bonds be-
tween pyrene and the derivatized methionine as well as be-
tween pyrene-Met and the next amino acid are stable (unpub-
lished results, Odom, Kramer and Hardesty). Thus the
N-terminal (radioactive) Met cannot be hydrolyzed by a me-
thionine aminopeptidase as would occur after deformylation
Fig. 1. Pause-site peptide pattern of CAT or silently mutated CAT.
A: CAT (lanes 1 and 2) or CAT from mutated mRNA (lanes 3 and
4) was synthesized using pyrene-[35S]Met-tRNA as the initiator
tRNA with either 5 Wl (lanes 1 and 3) or 2.5 Wl (lanes 2 and 4) of
S30/30 Wl of reaction mixture. These were incubated at 37‡C for
30 min, then an aliquot was analyzed by SDS^PAGE and phos-
phorimaging. The positions of the molecular weight markers are in-
dicated. B: The coding sequences for CAT (lane 1) or mutated
CAT (lane 2) were expressed for 30 min at 37‡C using 5 Wl of S30/
30 Wl of reaction mixture in the presence of a mixture of [14C]amino
acids (see Section 2.2). The translation products were analyzed by
SDS^PAGE and phosphorimaging.
Table 1
Enzymatic activity of CAT protein expressed from wild-type or mutated coding sequence
Protein from coding sequence Amount synthesized (ng) Full-length (%) Enzymatic activity
(UU1036) Protein (U/mg)
Wild-type CAT 15.4 80 523.1 41.2
Mutant CAT 16.7 70 373.6 31.8
Wild-type or silently mutated CAT mRNA was expressed by coupled transcription/translation under optimal conditions (using 5 Wl S30/30 Wl
reaction mixture) in the presence of a mixture of [14C]amino acids as described in Section 2.2. An aliquot was withdrawn after 30 min of incu-
bation at 37‡C, precipitated with trichloroacetic acid and its radioactivity determined. A second aliquot was analyzed by SDS^PAGE (see Fig.
1B) and phosphorimaging. Another aliquot was used to measure enzymatic activity.
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of a formyl group when the peptide is initiated with fMet-
tRNA. In other experiments, the CAT polypeptides were la-
beled during protein synthesis with a mixture of 15 [14C]L-
amino acids (see Section 2.2). These results are shown in
Fig. 1B for comparison and in relation to Table 1 below,
where speci¢c enzymatic activity is presented. Under these
conditions, full-length CAT is the prominent product.
3.2. Kinetics of expression of silently mutated CAT
It has been shown previously that nascent CAT peptides
initiated with coumarin-Met-tRNA could be shifted to full-
length product to some extent though pause-site peptides of
distinct sizes remained visible [2]. To eliminate the possibility
that the mutant form of the CAT coding sequence would
generate the same pause-site peptides but its mRNA was
translated much faster than that for the wild-type protein,
the kinetics of CAT synthesis were investigated. The results
are shown in Fig. 2. When CAT synthesis from the mutated
mRNA was initiated with pyrene-[35S]Met-tRNA, the full-
length product appeared after 5 min of incubation. Accumu-
lation of the low molecular mass peptides was not observed.
These were the more predominant products after 10 and 30
min of incubation in the case of wild-type CAT (see [17],
¢gure 4C).
3.3. Enzymatic activity of CAT
To investigate whether CAT synthesized from the mutated
coding sequence is folded correctly, its enzymatic activity was
measured and compared to that of wild-type CAT. Both wild-
type and mutated CAT coding sequences were expressed
under identical conditions in the presence of a mixture of 15
[14C]L-amino acids with the missing ¢ve amino acids added in
unlabeled form (see Section 2.2). Incubation was for 30 min at
37‡C. Then CAT enzymatic activity was determined using
[3H]acetyl-coenzyme A to quantitate the product of the reac-
tion. The SDS^PAGE analysis of an aliquot of the reaction
mixtures after coupled transcription/translation is shown in
Fig. 1B. The percentage of full-length polypeptide was esti-
mated. The total amount of protein synthesized was deter-
mined from incorporation of radioactive amino acids into
trichloroacetic acid-precipitable polypeptides. The results are
shown in Table 1. They indicate a reduced speci¢c enzymatic
activity for CAT synthesized from the mutated CAT mRNA
sequence. We hypothesize that this might be due to a faster
synthesis of CAT from this mRNA.
3.4. Possible cause for pause-site peptides and its elimination
Based on the results presented above in Section 3.1 and
shown in Fig. 1A, one might assume that the concentration
of the rare isoleucine tRNA species might be one of the major
factors in regulating ribosomal pausing at the codon for ami-
no acid 12 in the case of wild-type CAT. This was tested by
adding total E. coli tRNA to the coupled transcription/trans-
lation reaction mixture. Exogenously added tRNA up to 60
Wg/30 Wl reaction mixture had no e¡ect on the pause-site pat-
tern of wild-type CAT expression initiated with pyrene-Met-
tRNA except that overall protein synthesis was reduced by
about 20% (data not shown).
Fig. 2. Kinetics of CAT synthesis from the mutated mRNA initi-
ated with pyrene-[35S]Met-tRNA. CAT synthesis was initiated with
pyrene-[35S]Met-tRNA under optimal conditions. Reaction mixtures
were incubated, and at indicated times aliquots were withdrawn and
analyzed by SDS^PAGE and phosphorimaging.
Fig. 3. Predicted secondary structures for the ¢rst 60 nucleotides of wild-type and mutated CAT mRNA coding sequence. A = wild-type
mRNA; B = mutated mRNA.
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The secondary structures of the 5P 60 nucleotides of the two
CAT coding sequences were compared as predicted from the
mfold program [22]. This analysis (Fig. 3) suggests that the
secondary structures formed by the wild-type and the mutant
CAT mRNAs are slightly di¡erent with a change in the stem
structure formed with nucleotides 2^7 of the wild-type mRNA
and the size of the ¢rst loop. An increase in the overall stabil-
ity of the shown structure of the mutated CAT sequence was
predicted (39.7 kcal/mol versus 37.3 kcal/mol for the wild-
type).
4. Discussion
When synthesis of CAT was initiated with pyrene-Met-
tRNA, accumulation of a low molecular weight nascent pep-
tide was observed (Fig. 1A, lanes 1 and 2). The translational
pause site has been identi¢ed as the rare ATA encoding iso-
leucine in position 13 of the CAT amino acid sequence. As the
ATA codon for isoleucine occurs at a frequency of 0.4% in E.
coli cells [21] and since there exists a correlation between fre-
quency of codon usage and the level of its cognate tRNA, we
assumed that a large amount of exogenously added tRNA
would alleviate the translational pausing. This was not the
case. Up to 60 Wg E. coli tRNA was added to a 30 Wl reaction
mixture containing 5 Wl S30 fraction. This amount of S30
contains about 38 pmol of ribosomes of which maximally
20% are active in protein synthesis in vitro. That means about
7.6 pmol is translating ribosomes. The tRNA added should
contain about 9.6 pmol of the rare tRNAIle (the product of
the ileX gene) ^ theoretically enough to provide Ile for the
rare AUA codon of the mRNA.
Based on this calculation with its assumptions, we favor the
hypothesis that the change in mRNA structure due to the
mutation is the cause that eliminates the translational pause
site. We present this hypothesis though it is not evident to us
how the predicted change in mRNA structure (with a slight
increase in stability) could eliminate the pause site. Recently,
it has been proposed that ribosomes themselves have the abil-
ity to unwind mRNA secondary structure by an unknown
mechanism and the possible roles of the proteins S3, S4 and
S5 of the 30S subunit in binding and unwinding of an mRNA
helix have been suggested [23]. A small change in mRNA
structure may greatly facilitate this helicase action.
The puzzling observation is that the rare ATA codon close
to the 5P end of the CAT coding sequence has such a strong
e¡ect on translational pausing and only when protein synthe-
sis is initiated with £uorophore-Met-tRNA (Fig. 1A). As the
nascent CAT peptide with a bulky hydrophobic N-terminus
has to feed through relatively narrow passages in the riboso-
mal tunnel of the 50S subunit [24], a feature in mRNA struc-
ture may be a secondary determinant that a¡ects the elonga-
tion rate of the growing peptide chain.
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